Indication intelligence, analysis and sector perception

RegMed Investors

RegMed Investors <RMi> is the newsletter or portal focused on providing actionable intelligence, insightfull metrics and pricing synthesis of stem, gene and cell therapy companies demonstrating real progress toward their vision and meeting quarterly expectation.

Our mission is unchanged from the day we were founded: that is to provide original, objective and timely equity analysis and synthesis with an all-consuming intensity to "get it right" that reflects ... his personal commitment, ethics as well as his SEC certification.

RMi is now in its eleventh <11> year, having started in 2001 as an independent <Scimitar Equity> reseach firm which provided time sensitive research/analyst reports that focused fundamental, technical and qualitative narratives.

We bring years of experience <and some gray hair> in finance, capital markets, investment analysis, corporate operations and due diligence that defines our unique ability as an research/analysis provider.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.